具有改善的药理学和药物递送特性的GLP-1受体激动剂.pdf,公开了可用于活化胰高血糖素样肽‑1(GLP‑1)受体并治疗或预防至少部分由胰高血糖素样肽1(GLP‑1)介导的疾病或病症的多肽、组合物和方法。(19)国家知识产权局 (12)发明专利申请 (10)申请公布号 CN 118076367 A (4
, methods of decreasing gastric secretion and emptying and glucagons secretion, and methods of inhibiting food intake, and methods of treating diabetes mellitus, insulin resistance syndrome, hyperglycemia, and obesity comprising administering to a subject an effective amount of a TRPM5 inhibitor....
Active GLP-1 Assay[2] Recommend:Medicilon Assists CGeneTech's Oral Hypoglycemic DPP-4 Inhibitor, New Drug Application (NDA) Accepted Pharmacokinetic (PK) Studies of GLP-1 Medcilon provides high quality quantitative assays for key pharmacokinetic parameters in a GLP-1 PK study, presenting accurate...
Thrasher J, Woo V, Philis-Tsimikas A. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019 May;7(5):356-367
The insulin/IGF-1 signaling pathway plays a major role in body homeostasis, glucose regulation and has paracrine/autocrine functions in the brain, having in mind that the primary source of both peptides is mostly peripheral and not central (Abbas et al., 2008, Daftary and Gore, 2005, Kappel...
cardiovascular risks such as hypertension, hyperglycemia, dyslipidemia, overweight, and insulin resistance via various mechanisms. DPP-4 dipeptidyl peptidase-4, DPP-4i DPP-4 inhibitors, GLP-1 glucagon-like peptide-1, ApoB48 apolipoprotein B48, VLDL very low-density lipoprotein, LDL low-density ...
Liraglutide is a glucagon-like peptide-1 (GLP-1) mimetic used for the treatment of Type 2 diabetes. Similar to the actions of endogenous GLP-1, liraglutide potentiates the post-prandial release of insulin, inhibits glucagon release and increases satiety. Recent epidemiological studies and clinical ...
2022年3月,全球首个基础胰岛素胰高血糖素样肽-1受体激动剂(GLP-1RA)注射液——德谷胰岛素利拉鲁肽注射液(Insulin Degludec/Liraglutide Injection, 简称IDegLira)在中国上市,为 2 型糖尿病(T2DM)患者治疗提供一种全新的选择。 国家医保局医保药品目录结...
Functional antagonism between inhibitor of DNA binding (Id) and adipocyte determination and differentiation factor 1/sterol regulatory element-binding prot... We show that Id (inhibitor of DNA binding) 2 and Id3, domina...
了解GLP-1影响体重的相关机制。 自胰高糖素样肽-1(GLP-1)被发现以来,已然成为一种“多面手”激素——其接二连三的代谢功能被人们发现,远远超出了作为肠促胰素的经典定义。GLP-1众多有益的作用使其受体激动剂逐渐成为更多新兴的治疗领域如脂肪肝、肥胖和神经退行性疾病等的冉冉之“星”药物,而GLP-1的减重作用...